Timmerman Philip, White Stephen, McDougall Stuart, Kall Morten A, Smeraglia John, Fjording Marianne Scheel, Knutsson Magnus
Janssen R&D, Turnhoutseweg, 30, B-2340 Beerse, Belgium.
GlaxoSmithKline, Ware, UK.
Bioanalysis. 2015 Sep;7(18):2387-2398. doi: 10.4155/bio.15.168. Epub 2015 Sep 10.
The principles of tiered approach have been part of the bioanalytical toolbox for some years. Nevertheless, an in spite of many valuable discussions in industry, they remain difficult to apply in a harmonized way for a broad array of studies in early drug development where these alternative approaches to regulated validation would make sense. The European Bioanalysis Forum has identified the need to proposes some practical workflows for five categories of studies for chromatography based assays where scientific validation will allow additional freedom while safeguarding scientific rigor and robust documentation: quantification of metabolites in plasma in relation to ICH M3(R2), urine analysis, tissue homogenate analysis, and preclinical and clinical studies in early stages of drug development. The recommendation would introduce a common language and harmonized best practice for these study categories and can help to refocus towards optimized scientific and resource investments for bioanalysis in early drug development.
分层方法的原则多年来一直是生物分析工具的一部分。然而,尽管行业内进行了许多有价值的讨论,但在早期药物开发的大量研究中,仍难以以统一的方式应用这些原则,而在这些研究中,这些替代常规验证的方法是有意义的。欧洲生物分析论坛已确定有必要针对基于色谱分析的五类研究提出一些实用的工作流程,在科学验证能够在保障科学严谨性和完善记录的同时允许更多灵活性的情况下,这些研究包括:与ICH M3(R2)相关的血浆中代谢物的定量分析、尿液分析、组织匀浆分析以及药物开发早期的临床前和临床研究。该建议将为这些研究类别引入一种通用语言和统一的最佳实践,并有助于在早期药物开发中重新聚焦于生物分析的优化科学和资源投入。